Patents

Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.

Keywords:

Results 271 - 280 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patents
Patent No.: US 5955573
Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same.
Applicant: Garbarino J, Jaynes J, Belknap W (1999)
Stabilized ubiquitin-lytic peptide fusion polypeptides and a method of making the same by sub-cloning nucleic acid sequences coding for lytic peptides into a plasmid vector comprising a promoter and ubiquitin polypeptide coding sequence, wherein the ubiquitin polypeptide sequence is linked to the 5' end of the lytic peptide nucleic acid sequence and is translated as a fusion polypeptide.

Patent No.: US 5939393
Bactericidal factor in human airway surface fluid and uses thereof.
Applicant: Welsh MJ, Smith JJ, Travis SM, Greenberg EP (1999)
A bactericidal factor isolated from the surface fluid of airway epithelial cells and uses therefore is described. The bactericidal factor is characterized as having the following features: a) a molecular weight of less than 10 kD; b) heat stable; c) broad spectrum activity including gram positive and gram negative bacteria, fungi, and methicillin resistant Staphylococcus; and d) decreased antimicrobial activity in increasing salt concentration. The factor is a defensin-like mol. In cystic fibrosis (CF) patients which have abnormal levels of salt concn. in the airways due to defective Cl- transport, the factor is inactivated. leading for the first time to the explanation of the pulmonary infection assocd. with CF.

Patent No.: US 5916872
Cyclic peptides having broad spectrum antimicrobial activity.
Applicant: Chang C, Gu L, Chen J (1999)
The present invention provides cyclic peptides having broad spectrum antimicrobial activity. The peptides exhibit improved efficacy, bioavailability and/or serum half-life as compared with non-cyclized analogues.

Patent No.: US 5910306
Transdermal delivery system for antigen.
Applicant: Alving CR, Glenn GM (1999)
A transdermal liposome system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses liposomes to deliver a variety of antigens which can elicit an antigen-specific immune response (e.g., humoral and/or cellular effectors) after topical application of a formulation containing liposomes and antigen to intact skin of the animal or human.

Patent No.: US 5905187
Antimicrobial peptides and plant disease resistance based thereon.
Applicant: Duvick JP, Rood TA, Rao AG (1999)
CMIII, a small, basic maize seed peptide has been found to have antimicrobial properties. CMIII is surprisingly similar to a mammalian antimicrobial peptide, defensin NP1 from rabbits, although CMIII is much higher in glutamate and has 4 rather than 6 cysteines. A gene or cDNA encoding the CMIII peptide is useful in the generation of transgenic plants resistant to a no. of microbial pathogens. Purifn. of CMIII from H2SO4 exts. of maize seeds and its antimicrobial properties are described. Cloning of a cDNA or gene for the CMIII peptide and its expression in transgenic corn are discussed.

Patent No.: US 5891341
Compositions and devices for partitioning advanced glycosylation endproducts, and methods of their use.
Applicant: Li YM, Vlassara H, Cerami A (1999)
The present invention is directed to compositions and devices based upon the unexpected discovery that certain antibacterial proteins, in particular lysozyme and lactoferrin, bind to advanced glycosylation endproducts (AGEs) with high affinity, and that this binding activity is substantially noncompetitive with binding of bacterial carbohydrates to the antibacterial proteins. Accordingly, the invention relates to methods for treating diseases and disorders associated with increased levels of AGEs, by using compositions and devices having associated therewith a molecule having a hydrophilic loop domain, which domain is associated with AGE-binding activity, and compositions comprising such a domain. The invention further relates to compositions and devices for partitioning AGEs away from a sample.

Patent No.: US 5877151
Method for inhibiting production of tumor necrosis factor.
Applicant: Pereira HA (1999)
The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.

Patent No.: US 5865744
Method and system for delivering therapeutic agents.
Applicant: Lemelson JH (1999)
A system and method are disclosed for internally delivering a therapeutic agent to a patient under the automatic control of a computer. A diagnostic imaging modality, such as a CAT or MRI scanning system, generates one or more images of the patient's anatomy showing an anatomical region into which it is desired to deliver the cellular transplants. For each such image, location coordinates with respect to a patient support means are calculated by the computer for each individual pixel making up the image. Location coordinates are then defined for a select body region corresponding to pixels of the anatomical image(s) designated by a user of the system to receive the therapeutic agent. The computer then operates a manipulator arm in order to position an injection tool such as an injection needle or catheter mounted on the arm adjacent to the select body region. In the case of an injection needle, the needle is inserted into the region at the appropriate depth, and an injector is operated under computer control to force a predetermined amount of a medium containing the therapeutic agent out of a lumen within the injection needle and into the select body region.

Patent No.: US 5861378
Horseshoe crab hemocyte polypeptides, and preparation and DNA encoding thereof.
Applicant: Iwanaga S, Kawabata S, Saito T (1999)
The present invention relates to polypeptide having a primary structure of amino acid sequence shown by Sequence List Sequence No. 1 and DNA encoding for the polypeptide. The polypeptide is obtainable by following steps (1)-(3): Step (1): extracting small granule fraction of homocytes of horseshoe crab with a buffer containing protein denaturing agent and chelating agent, Step (2): subjecting said extract to reverse phase high performance liquid chromatography, Step (3): eluting by concentration gradient elution with a hydrophobic organic solvent. Also, the polypeptide is produced by chemical synthesis. The polypeptide has similar chemical structure to defensin and is useful as gargles, disinfectants, antiseptics or antimicrobials.

Patent No.: US 5861238
Methods for partitioning advanced glycosylation endproducts.
Applicant: Li YM, Vlassara H, Cerami A (1999)
The present invention is directed to methods for partitioning advanced glycosylation endproducts out of a biological sample using the unexpected discovery that certain antibacterial proteins, in particular lysozyme and particular fragments thereof, bind to advanced glycosylation endproducts (AGEs) with high affinity, and that this binding activity is substantially noncompetitive with binding of bacterial carbohydrates to the antibacterial proteins. Accordingly, the invention relates to therapeutic methods for treating diseases and disorders associated with increased levels of AGEs, by using compositions having associated therewith a molecule having a hydrophilic loop domain, which domain is associated with AGE-binding activity, and compositions comprising such a domain to remove AGEs from biological material. The invention further relates to compositions and devices for partitioning AGEs away from a sample.